Drug Trial Radar · NCT05608837
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
28
Actual
Start
May 26, 2023
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Quan Dong NguyenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Global Ophthalmic Research Center (GORC); Oculis
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01. Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision. In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery. Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.
Conditions
- Uveitis Related Cystoid Macular Edema
- Cystoid Macular Edema, Postoperative
Interventions
OCS-01Drug
One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Central Subfield ThicknessTime frame: Baseline to 12 weeks
- Visual AcuityTime frame: Baseline to 12 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Retina Vitreous Associates Medical Group
Beverly Hills, California
Retina Associates of Southern California
Huntington Beach, California
Stein Eye Institute at UCLA
Los Angeles, California
Byers Eye Institute at Stanford
Palo Alto, California
Massachusetts Eye Research and Surgery Institution
Boston, Massachusetts
Erie Retina Research
Erie, Pennsylvania
Valley Retina Institute P.A
McAllen, Texas
Texas Retina Associates
Plano, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.